Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma

Xuqing Shen; Ningning Niu; Jing Xue

doi:10.2478/jtim-2022-0022

Oncogenic KRAS triggers metabolic reprogramming in pancreatic ductal adenocarcinoma

J Transl Int Med. 2022 Nov 15;11(4):322-329. doi: 10.2478/jtim-2022-0022. eCollection 2023 Dec.

Authors

Xuqing Shen¹, Ningning Niu¹, Jing Xue¹

Affiliation

¹ State Key Laboratory of Oncogenes and Related Genes, Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai 200127, China.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with an extremely high lethality rate. Oncogenic KRAS activation has been proven to be a key driver of PDAC initiation and progression. There is increasing evidence that PDAC cells undergo extensive metabolic reprogramming to adapt to their extreme energy and biomass demands. Cell-intrinsic factors, such as KRAS mutations, are able to trigger metabolic rewriting. Here, we update recent advances in KRAS-driven metabolic reprogramming and the associated metabolic therapeutic potential in PDAC.

Keywords: metabolic reprogramming; oncogenic KRAS activation; pancreatic ductal adenocarcinoma.

Grants and funding

This work was supported by National Natural Science Foundation of China (No. 82022049, Xue J; No. 82073105, Niu N), Shanghai Rising-Star Program (19QA1408300, Niu N), the Science and Technology Commission of Shanghai Municipality (20ZR1432900, Niu N), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (No. 20161312, Xue J), and State Key Laboratory of Oncogenes and Related Genes (KF2113, Niu N).